| Literature DB >> 35056420 |
Tsuyoshi Nakagawa1, Goshi Oda1, Hiroki Mori2, Noriko Uemura2, Iichiro Onishi3, Noriko Sagawa1, Tomoyuki Fujioka4, Mio Mori4, Kazunori Kubota4, Toshiaki Ishikawa5, Kentaro Okamoto5, Hiroyuki Uetake5.
Abstract
Background and objectives: In the treatment of the special type of breast cancer (STBC), the choice of chemotherapeutic agents is often based on the characteristic features of the histological type. On the other hand, the surgical strategy is usually determined by the tumor size and presence of lymph node metastasis, and the indication for immediate reconstruction is rarely discussed based on the histological type. The prognoses of STBC and invasive ductal carcinoma of the breast (IDC) patients who underwent subcutaneous mastectomy (SCM) with immediate reconstruction at our institution were compared. Materials andEntities:
Keywords: breast cancer; lobular carcinoma; mucinous carcinoma; special type; subcutaneous mastectomy
Mesh:
Year: 2022 PMID: 35056420 PMCID: PMC8780999 DOI: 10.3390/medicina58010112
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Background characteristics of all patients.
| Characteristics | Total (254) | IDC (211) | STBC (43) |
| |
|---|---|---|---|---|---|
| Age (Mean) | 26–72 (46) | 26–72 (45) | 31–64 (48) | ||
| Type of subcutaneous mastectomy | Skin sparing mastectomy | 166 | 145 | 21 | 1 |
| Nipple sparing mastectomy | 88 | 75 | 13 | ||
| Operation on axillary lymph nodes | Sentinel Lymph node biopsy | 129 | 113 | 16 | 0.493 |
| Sentinel Lymph node biopsy → Axillary lymph node dissection | 45 | 37 | 8 | ||
| Axillary lymph node dissection | 80 | 70 | 10 | ||
| Reconstruction method | TRAM/VRAM | 31 | 26 | 5 | 0.623 |
| DIEP | 43 | 38 | 5 | ||
| LD | 63 | 54 | 9 | ||
| TE | 117 | 102 | 15 | ||
| Post mastectomy irradiation | No | 247 | 215 | 32 | 0.338 |
| Yes | 7 | 5 | 2 | ||
| Histological type | Invasive ductal carcinoma | 211 | 211 | - | - |
| Special type | 43 | - | 43 | ||
| Mucinous carcinoma | 17 | - | 17 | ||
| Invasive lobular carcinoma | 17 | - | 17 | ||
| Apocrine carcinoma | 6 | - | 6 | ||
| Tubular carcinoma | 1 | - | 1 | ||
| Invasive micropapillary carcinoma | 2 | - | 2 | ||
| Tumor size | 1 | 150 | 137 | 13 | 0.0651 |
| 2 | 94 | 78 | 16 | ||
| 3 | 10 | 5 | 5 | ||
| Lymph node metastasis | No | 179 | 155 | 24 | 0.856 |
| Yes | 75 | 65 | 10 | ||
| Nuclear grade | 1 | 143 | 113 | 30 | 0.0004 |
| 2 | 59 | 55 | 4 | ||
| 3 | 52 | 52 | 0 | ||
| Estrogen receptor | Positive | 223 | 192 | 31 | 0.441 |
| Negative | 31 | 28 | 3 | ||
| HER2 | Positive | 20 | 19 | 1 | 1 |
| Negative | 234 | 201 | 33 | ||
| Lymphatic vessel invasion | Positive | 36 | 32 | 4 | 0.811 |
| Negative | 218 | 188 | 30 | ||
| Blood vessel invasion | Positive | 17 | 16 | 1 | 0.32 |
| Negative | 237 | 204 | 33 | ||
| Adjuvant chemotherapy | No | 191 | 164 | 27 | 1 |
| Yes | 63 | 56 | 7 | ||
| Distant Metastasis | No | 228 | 197 | 31 | 0.586 |
| Yes | 26 | 23 | 3 | ||
| Survival | Alive | 233 | 199 | 34 | 0.03 |
| Dead | 21 | 21 | 0 | ||
| Local Recurrence | No | 237 | 205 | 32 | 0.745 |
| Yes | 17 | 15 | 2 | ||
Figure 1Comparison of prognosis between IDC and STBC. (A) DFS: There was no significant difference in DFS between the IDC and STBC groups. (B) OS: There were no deaths in the STBC group, and OS was significantly longer in the STBC group (p = 0.0266). (C) LRFS: There was no significant difference in LRFS between the IDC and STBC groups.
Background characteristics of patients with MUC and ILC.
| Characteristics | Total (34) | Mucinous Carcinoma (17) | Invasive Lobular Carcinoma (17) |
| |
|---|---|---|---|---|---|
| Age (Mean) | 31–64 (48) | 31–62 (45) | 38–64 (50) | - | |
| Type of subcutaneous mastectomy | Skin sparing mastectomy | 21 | 7 | 14 | 0.0324 |
| Nipple sparing mastectomy | 13 | 10 | 3 | ||
| Operation on axillary lymph nodes | Sentinel Lymph node biopsy | 16 | 8 | 8 | 0.18 |
| Sentinel Lymph node biopsy → Axillary lymph node dissection | 8 | 2 | 6 | ||
| Axillary lymph node dissection | 10 | 7 | 3 | ||
| Reconstruction method | TRAM/VRAM | 5 | 2 | 3 | 0.223 |
| DIEP | 5 | 1 | 4 | ||
| LD | 9 | 7 | 2 | ||
| TE | 15 | 7 | 8 | ||
| Post mastectomy irradiation | No | 32 | 17 | 15 | 0.485 |
| Yes | 2 | 0 | 2 | ||
| Pure/Mixed type | Pure | 19 | 7 | 12 | 0.166 |
| Mixed | 15 | 10 | 5 | ||
| Tumor size | 1 | 13 | 6 | 7 | 0.0262 |
| 2 | 16 | 11 | 5 | ||
| 3 | 5 | 0 | 5 | ||
| Lymph node metastasis | No | 24 | 14 | 10 | 0.259 |
| Yes | 10 | 3 | 7 | ||
| Nuclear grade | 1 | 30 | 15 | 15 | 1 |
| 2 | 4 | 2 | 2 | ||
| 3 | 0 | 0 | 0 | ||
| Estrogen receptor | Positive | 31 | 14 | 17 | 0.227 |
| Negative | 3 | 3 | 0 | ||
| HER2 | Positive | 1 | 1 | 0 | 1 |
| Negative | 33 | 16 | 17 | ||
| Lymphatic vessel invasion | Positive | 4 | 2 | 2 | 1 |
| Negative | 30 | 15 | 15 | ||
| Blood vessel invasion | Positive | 1 | 0 | 1 | 1 |
| Negative | 33 | 17 | 16 | ||
| Adjuvant chemotherapy | No | 27 | 16 | 11 | 0.0854 |
| Yes | 7 | 1 | 6 | ||
| Distant Metastasis | No | 31 | 14 | 17 | 0.227 |
| Yes | 3 | 3 | 0 | ||
| Survival | Alive | 34 | 17 | 17 | 1 |
| Dead | 0 | 0 | 0 | ||
| Local Recurrence | No | 32 | 15 | 17 | 0.485 |
| Yes | 2 | 2 | 0 | ||
Figure 2Comparison of prognosis between MUC and ILC. (A) DFS, (B) OS, (C) LRFS. There were no statistically significant differences in DFS, OS, or LRFS between the MUC and ILC groups.